Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FronThera
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Frontera Therapeutics has demonstrated strong early clinical results, with multiple rAAV gene therapy programs in Phase 2. FT-003 (anti-VEGF) reported superior efficacy and safety in Phase 2 for nAMD/DME. FT-002 (RPGR, XLRP) and FT-001 (RPE65, LCA2) are in Phase 2 and have shown improvement in retinal function. Hematology and cardiology programs are at earlier development stages.
- Therapeutic areas
- HematologyOphthalmologyCardiovascular
- Modalities
- Gene therapyRecombinant adeno-associated virus (rAAV)-based therapy
- Industry
- Biotech
Beyond the preview
Go deeper on FronThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FronThera.